ES2986594T3 - Nuevos derivados de cromano que tienen actividad de degradación del receptor de estrógeno y usos de los mismos - Google Patents
Nuevos derivados de cromano que tienen actividad de degradación del receptor de estrógeno y usos de los mismos Download PDFInfo
- Publication number
- ES2986594T3 ES2986594T3 ES20169240T ES20169240T ES2986594T3 ES 2986594 T3 ES2986594 T3 ES 2986594T3 ES 20169240 T ES20169240 T ES 20169240T ES 20169240 T ES20169240 T ES 20169240T ES 2986594 T3 ES2986594 T3 ES 2986594T3
- Authority
- ES
- Spain
- Prior art keywords
- dione
- piperidine
- piperazin
- oxoisoindolin
- cis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962947213P | 2019-12-12 | 2019-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2986594T3 true ES2986594T3 (es) | 2024-11-12 |
Family
ID=70289288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20169240T Active ES2986594T3 (es) | 2019-12-12 | 2020-04-13 | Nuevos derivados de cromano que tienen actividad de degradación del receptor de estrógeno y usos de los mismos |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10800770B1 (enExample) |
| EP (2) | EP3835298B1 (enExample) |
| JP (2) | JP7662639B2 (enExample) |
| KR (1) | KR102942706B1 (enExample) |
| CN (2) | CN115003295B (enExample) |
| CA (1) | CA3164202A1 (enExample) |
| DK (1) | DK3835298T3 (enExample) |
| ES (1) | ES2986594T3 (enExample) |
| FI (1) | FI3835298T3 (enExample) |
| MX (1) | MX2022007155A (enExample) |
| WO (1) | WO2021118629A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL266842B (en) | 2016-12-01 | 2022-09-01 | Arvinas Operations Inc | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists |
| EP3932922A4 (en) | 2019-02-25 | 2022-05-11 | ShanghaiTech University | SULPHUR-CONTAINING COMPOUND BASED ON A GLUTARIMIDE FRAMEWORK AND ITS USE |
| WO2021023233A1 (zh) | 2019-08-05 | 2021-02-11 | 上海科技大学 | Egfr蛋白降解剂及其抗肿瘤应用 |
| WO2021041348A1 (en) | 2019-08-26 | 2021-03-04 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| CN115003295B (zh) * | 2019-12-12 | 2025-05-06 | 冰洲石生物科技公司 | 具有雌激素受体降解活性的新型色满衍生物及其用途 |
| CN116234803B (zh) * | 2019-12-23 | 2026-06-30 | 冰洲石生物科技公司 | 用于治疗癌症的雌激素受体降解剂和细胞周期蛋白依赖性激酶抑制剂的组合 |
| AU2021226514B2 (en) * | 2020-02-25 | 2023-10-19 | Shanghaitech University | Glutarimide skeleton-based compounds and application thereof |
| AU2021342287A1 (en) | 2020-09-14 | 2023-04-13 | Arvinas Operations, Inc. | Crystalline forms of a compound for the targeted degradation of estrogen receptor |
| US12655135B2 (en) | 2021-02-04 | 2026-06-16 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Benzo seven-membered ring bifunctional compound and application thereof |
| WO2022187588A1 (en) * | 2021-03-04 | 2022-09-09 | The Regents Of The University Of Michigan | Small molecule degraders of estrogen receptor with cereblon ligands |
| JP2024512544A (ja) * | 2021-03-29 | 2024-03-19 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | テトラヒドロナフタレン系化合物、その製造方法及びその医薬的応用 |
| KR20240040769A (ko) | 2021-07-26 | 2024-03-28 | 아비나스 오퍼레이션스, 인코포레이티드 | 이작용성 화합물을 제조하는 방법 |
| JP2024539269A (ja) * | 2021-10-22 | 2024-10-28 | グルータクス セラピューティクス （シャンハイ） カンパニー、リミテッド | Ｃｒｂｎ ｅ３リガーゼリガンド化合物、当該リガンド化合物に基づいて開発したタンパク質分解剤及びそれらの応用 |
| CN113816927B (zh) * | 2021-11-23 | 2022-02-25 | 苏州国匡医药科技有限公司 | 一种arv-471中间体的制备方法 |
| US12662467B2 (en) | 2022-04-18 | 2026-06-23 | BioThery X, Inc. | Isoindolinones, pharmaceutical compositions, and therapeutic applications |
| CN117229286A (zh) | 2022-06-14 | 2023-12-15 | 海创药业股份有限公司 | 一种芳香类化合物及其制备方法及在制备雌激素受体降解剂中的用途 |
| US20260000676A1 (en) * | 2022-07-12 | 2026-01-01 | The Regents Of The University Of Michigan | Chroman derivatives as estrogen receptor degraders |
| CN116751186B (zh) * | 2022-12-23 | 2024-10-18 | 南京知和医药科技有限公司 | 一种雌激素受体调节剂的制备及其用途 |
| CN120615091A (zh) * | 2023-01-16 | 2025-09-09 | 正大天晴药业集团股份有限公司 | 取代的苯并七元环化合物及其应用 |
| CN119258223A (zh) * | 2023-07-06 | 2025-01-07 | 海创药业股份有限公司 | 一种降解雌激素受体的联合用药物及其用途 |
| WO2025245408A1 (en) | 2024-05-22 | 2025-11-27 | Accutar Biotechnology Inc. | Chroman-based compounds for treating cancer |
| WO2026138908A1 (zh) * | 2024-12-24 | 2026-07-02 | 海创药业股份有限公司 | 一种雌激素受体降解剂中间体及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4772397A (en) * | 1996-10-28 | 1998-05-22 | Novo Nordisk A/S | Novel (cis)-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes |
| AU4772297A (en) * | 1996-10-28 | 1998-05-22 | Novo Nordisk A/S | Novel (cis)-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes |
| US20010021710A1 (en) * | 1996-10-28 | 2001-09-13 | Poul Jacobsen | Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes |
| EP1192945A3 (en) * | 2000-09-21 | 2004-03-03 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating osteoarthritis |
| WO2003063859A1 (en) * | 2002-01-14 | 2003-08-07 | Nordic Bioscience A/S | Suppression of cartilage degradation via the estrogen receptor |
| WO2003063659A1 (de) | 2002-02-01 | 2003-08-07 | Danny Bellens | Ablageständer |
| CA2512000C (en) * | 2002-12-26 | 2011-08-09 | Eisai Co., Ltd. | Selective estrogen receptor modulator |
| SG183257A1 (en) * | 2010-02-11 | 2012-09-27 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| JP6768711B2 (ja) * | 2015-05-26 | 2020-10-14 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 複素環式エストロゲン受容体モジュレーター及びその使用 |
| HK1257296A1 (zh) * | 2016-07-12 | 2019-10-18 | Accutar Biotechnology Inc. | 新的化合物及其用途 |
| IL266842B (en) * | 2016-12-01 | 2022-09-01 | Arvinas Operations Inc | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists |
| CN115003295B (zh) * | 2019-12-12 | 2025-05-06 | 冰洲石生物科技公司 | 具有雌激素受体降解活性的新型色满衍生物及其用途 |
-
2020
- 2020-04-13 CN CN202080092528.XA patent/CN115003295B/zh active Active
- 2020-04-13 EP EP20169240.7A patent/EP3835298B1/en active Active
- 2020-04-13 CN CN202510495956.1A patent/CN120665056A/zh active Pending
- 2020-04-13 US US16/846,492 patent/US10800770B1/en active Active
- 2020-04-13 JP JP2022535123A patent/JP7662639B2/ja active Active
- 2020-04-13 DK DK20169240.7T patent/DK3835298T3/da active
- 2020-04-13 MX MX2022007155A patent/MX2022007155A/es unknown
- 2020-04-13 KR KR1020227023616A patent/KR102942706B1/ko active Active
- 2020-04-13 CA CA3164202A patent/CA3164202A1/en active Pending
- 2020-04-13 WO PCT/US2020/027895 patent/WO2021118629A1/en not_active Ceased
- 2020-04-13 FI FIEP20169240.7T patent/FI3835298T3/fi active
- 2020-04-13 ES ES20169240T patent/ES2986594T3/es active Active
- 2020-04-13 EP EP24170522.7A patent/EP4420728A3/en active Pending
- 2020-06-22 US US16/907,548 patent/US11261178B2/en active Active
-
2025
- 2025-02-03 JP JP2025015907A patent/JP2025081364A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7662639B2 (ja) | 2025-04-15 |
| US20210221802A1 (en) | 2021-07-22 |
| CN115003295A (zh) | 2022-09-02 |
| FI3835298T3 (fi) | 2024-07-29 |
| EP4420728A3 (en) | 2024-10-30 |
| CN120665056A (zh) | 2025-09-19 |
| WO2021118629A1 (en) | 2021-06-17 |
| KR102942706B1 (ko) | 2026-03-20 |
| EP4420728A2 (en) | 2024-08-28 |
| KR20220118460A (ko) | 2022-08-25 |
| MX2022007155A (es) | 2022-10-07 |
| JP2025081364A (ja) | 2025-05-27 |
| CN115003295B (zh) | 2025-05-06 |
| JP2023506155A (ja) | 2023-02-15 |
| US11261178B2 (en) | 2022-03-01 |
| CA3164202A1 (en) | 2021-06-17 |
| US10800770B1 (en) | 2020-10-13 |
| DK3835298T3 (da) | 2024-07-29 |
| EP3835298A1 (en) | 2021-06-16 |
| EP3835298B1 (en) | 2024-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7662639B2 (ja) | エストロゲン受容体分解活性を有する新規クロマン誘導体およびその使用 | |
| EP3675839B1 (en) | Novel compounds having estrogen receptor alpha degradation activity and uses thereof | |
| CN114945566B (zh) | 作为钠通道调节剂的取代四氢呋喃 | |
| JP7307796B2 (ja) | アンドロゲン受容体分解活性を有する新規の置換キノリン－８－カルボニトリル誘導体およびその使用 | |
| US11220490B2 (en) | Ureas having androgen receptor degradation activity and uses thereof | |
| CA2986930C (en) | Chemical modulators of signaling pathways and therapeutic use | |
| EP3390374A1 (en) | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels | |
| KR20190039125A (ko) | 신규한 화합물 및 이의 용도 | |
| EP4499148A1 (en) | Cyclin-dependent kinase 9 (cdk9) degraders and methods of using thereof | |
| ES2664418T3 (es) | Compuestos de fluorofenil pirazol | |
| EP4053108A1 (en) | Compound containing benzene ring and application thereof | |
| HK40115205A (en) | Novel chroman derivatives having estrogen receptor degradation activity and uses thereof |